Interestingly, a retrospective analysis of the Her2 status of the Danish DBCG 82 b and c trials [15] showed that RT (chest wall + LN) after mastectomy results in no improvement of overall survival in Her2 positive breast cancer, but in a 10 % overall survival gain in hormone receptor positive cancer. This evidence concerns the gene ERBB2 and breast carcinoma.